Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Must have received: DNA methyltransferase inhibitor — MDS

prior DNA methyltransferase inhibitor (DNMTi) treatment and progression after 2 cycles or stable disease after 4 cycles

Must have received: any anti-leukemia therapy — AML

relapsed or refractory following >= 1 line(s) of therapy

Cannot have received: SINE compound or other XPO1 inhibitor

Prior treatment with SINE compounds or other inhibitors of XPO1

Cannot have received: allogeneic hematopoietic stem cell transplant or other cellular therapy product

Exception: allowed if >3 months since transplant

History of allogeneic hematopoietic stem cell transplant (HCT), or other cellular therapy product, within 3 months

Cannot have received: radiation therapy

Exception: allowed if >3 weeks since therapy

Radiation therapy or major surgery within 3 weeks

Cannot have received: major surgery

Exception: allowed if >3 weeks since surgery

Radiation therapy or major surgery within 3 weeks

Cannot have received: anticancer therapy, including investigational agents

Exception: allowed if >2 weeks or >5 half-lives of drug, whichever is shorter, prior to C1D1; hydroxyurea permitted

Anticancer therapy, including investigational agents <= 2 weeks or <= 5 half-lives of the drug, whichever is shorter, prior to C1D1. (Use of hydroxyurea is permitted).